Sunday, September 17, 2006 

Mesothelioma - Annie Jennings


Annie Jennings
PRWeb - You do not need any permission to link to any of the pages on this site. Limited copyright is granted for you to use and/or republish any of the press releases on this site for any legitimate media purpose as long as you reference PRWeb as the source

Alfacell Updates Progress on Clinical Development Program for ONCONASE
PR Newswire - This pivotal trial is evaluating the effectiveness of ONCONASE plus doxorubicin in improving the survival of patients with unresectable malignant mesothelioma (UMM) over doxorubicin alone. The Company's Chief Executive Officer and Chairman of the